What is Anavex Life Sciences Corp.'s (AVXL) StockRank?

MoatMap's StockRank for Anavex Life Sciences Corp. (AVXL) is 5/100, with a Strong Sell signal. This is a composite score combining Quality (31), Value (30), and Momentum (15) factor ranks across MoatMap's 20,000+ stock universe.

Does Anavex Life Sciences Corp. have an economic moat?

Anavex Life Sciences Corp. (AVXL) has a Quality factor score of 31/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Anavex Life Sciences Corp. a buy, hold, or sell?

MoatMap's current signal for Anavex Life Sciences Corp. (AVXL) is Strong Sell, based on a StockRank of 5/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Anavex Life Sciences Corp. in?

Anavex Life Sciences Corp. (AVXL) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

AVXL

STRONG SELLREMOVE

Anavex Life Sciences Corp. · Healthcare · United States · $250M · Avg Vol: $4M/d

StockRank

P/E (TTM)

—

ROE

-33.6%

D/E

—

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

A clinical-stage biotech focused on CNS disorders that is highly speculative, pre-revenue, and does not possess the high-quality, cash-generative characteristics of our target investments.

COMPANY DESCRIPTION

Anavex Life Sciences is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative and neurodevelopmental diseases, with lead candidate blarcamesine targeting conditions like Alzheimer's and Rett syndrome. The company leverages a novel small molecule mechanism of action, focusing on sigma-1 and muscarinic receptor activation in areas with significant unmet medical need. It operates as a niche pipeline-driven biopharma firm, with valuation tied to clinical trial progress and regulatory approvals.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-0.62	-0.60	-0.52	-0.54	—
Shares	77.9M	82.1M	84.8M	86.7M	+11.2%
Debt	10.2M	12.5M	15.3M	8.9M	-4.3%
Equity	142.5M	141.9M	120.3M	94.9M	-12.7%
Op CF	-24.2M	-27.8M	-30.8M	-39.0M	—
Inv CF	—	—	—	—	—
Fin CF	21.3M	29.7M	12.0M	9.4M	—

PRICE (1Y)-16.3%

SMA 50SMA 200

$2.56

RSI (14)

46.3

52W High

$13.99

From 52W High

0.2%

SCORE BREAKDOWN

Quality

ROIC

-48.9%14.8

ROE

-33.6%23.9

GP/Assets

—N/A

Op. Margin

0.0%40.6

FCF/Assets

-21.0%16.1

Piotroski

212.0

Int. Cover

—N/A

D/E Ratio

—N/A

Current Ratio

20.87x95.7

Value

P/E (TTM)

—N/A

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

1.9x60.3

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

18%2.2

RS 6M

-39%31.0

SMA 50/200

0.61x2.4

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-20%14.7

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$250M

P/E (Forward)

-4.8x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AVXL are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
AVXL	Anavex Life Sciences Corp.(you)	$250M	5	STRONG SELL
FHTX	Foghorn Therapeutics Inc.	$248M	6	STRONG SELL
NMRA	Neumora Therapeutics, Inc.	$281M	6	STRONG SELL
LYEL	Lyell Immunopharma, Inc.	$288M	6	STRONG SELL
HUMA	Humacyte, Inc.	$237M	1	STRONG SELL
IVVD	Invivyd, Inc.	$280M	8	STRONG SELL
WHWK	Whitehawk Therapeutics, Inc.	$236M	9	STRONG SELL
GALT	Galectin Therapeutics Inc.	$188M	4	STRONG SELL
ARMP	Armata Pharmaceuticals, Inc.	$254M	12	STRONG SELL
UPB	Upstream Bio, Inc.	$350M	6	STRONG SELL

Peer medians: ROE -22.0% · P/E 25.1x · Gross margin 44.3%

Anavex Life Sciences Corp. (AVXL) — Stock Score Summary

Anavex Life Sciences Corp. (AVXL) has a MoatMap StockRank of 5/100 based on Quality (31/100), Value (30/100), and Momentum (15/100) factor scores. The current signal is STRONG SELL. A clinical-stage biotech focused on CNS disorders that is highly speculative, pre-revenue, and does not possess the high-quality, cash-generative characteristics of our target investments.

Key Financial Metrics

Price	$2.56
Market Cap	$250M
P/E (Forward)	-4.80
Price/Book	1.93
Return on Equity	-33.6%
Return on Invested Capital	-48.9%
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-22M

Anavex Life Sciences Corp. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Anavex Life Sciences Corp.’s (AVXL) StockRank?: MoatMap’s StockRank for Anavex Life Sciences Corp. (AVXL) is 5/100, with a Strong Sell signal. It is a composite of Quality (31), Value (30), and Momentum (15) factor ranks across MoatMap’s 20,000+ stock universe.
Does Anavex Life Sciences Corp. have an economic moat?: Anavex Life Sciences Corp. (AVXL) has a Quality factor score of 31/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Anavex Life Sciences Corp. a buy, hold, or sell?: MoatMap’s current signal for Anavex Life Sciences Corp. (AVXL) is Strong Sell, based on a StockRank of 5/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Anavex Life Sciences Corp. in?: Anavex Life Sciences Corp. (AVXL) operates in the Healthcare sector, specifically the Biotechnology industry (United States).